This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
27
Novo Nordisk Investigational Site
Santa Barbara, California, United States
Postprandial glycemic control
HbA1c (glycosylated haemoglobin A1c)
Postprandial endogenous insulin secretory response
Hypoglycemic episodes
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.